Moderna’s new mRNA (messenger Ribonucleic Acid) flu shot completed the phase 3 trials with succeeding data. They are aiming to launch in early 2024. The flu vaccine – mRNA-1010 has produced an immune response against all four A and B strains – A/H1N1, A/H3N2, influenza B/Yamagata, and B/Victoria.
Bayer confirms the positive results of their Parkinson’s stem cell therapy initial trial developed by their subsidiary BlueRock Therapeutics. The trial was conducted on 12 [Read More…]
The new variant of COVID-19 was initially found in Denmark on July 24 in a patient with severe symptoms and gradually found in other symptomatic patients during sample testing and screening.
The United States FDA grants accelerated approval for Pfizer’s therapy for the treatment of blood cancer (type)-affected patients which is difficult to treat.
The first oral drug suggested to treat postpartum depression (PPD) in adults, Zurzuvae (zuranolone), has received approval from the U.S. Food and Drug Administration. PPD [Read More…]
Fletcher, CC BY 4.0, via Wikimedia Commons Fletcher Moderna Inc reported a profit of 19 cents per share on Thursday. This trashed their expectation [Read More…]
Pfizer, Team, Public domain, via Wikimedia Commons FDA approves Pfizer’s new pneumococcal vaccines for children and infants on 27th April. The vaccine called Prevenar 20 [Read More…]
Novavax, Public domain, via Wikimedia Commons Maryland-based vaccine maker Novavax introduced a COVID-19 booster and flu combination vaccine candidate at the World Vaccine Congress in [Read More…]
